Immunex regulatory update

IMNX's Leukine GM-CSF received FDA marketing clearance for use following allogeneic bone marrow transplantation from HLA-matched related donors. In this indication, Leukine shortened the time to white blood cell recovery, and decreased the overall incidence of infection (75 percent in the placebo group versus 57 percent of treated patients) and the length of hospital stays. Leukine also signficantly reduced severe mucositis. ...